Menovazin

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT MENOVASIN

Composition:

Active substances: menthol, novocaine (procaine hydrochloride), anestezine (benzocaine);

100 ml of solution contains menthol – 2.5 g, novocaine (procaine hydrochloride) – 1 g, anestezine (benzocaine) – 1 g;
Excipient: ethanol 70%.

Pharmaceutical form.
Alcoholic solution for external use.

Main physicochemical properties: colorless, clear liquid with a menthol odor.

Pharmacotherapeutic group.
Agents applied locally for joint and muscular pain. ATC code: M02A X.

Pharmacological properties.

Pharmacodynamics. The drug has anti-itch and local anesthetic effects. When applied to the skin and mucous membranes, it stimulates nerve endings, causing sensations of cold, mild burning, and tingling.

It exerts a mild analgesic effect.

Pharmacokinetics. When applied locally, the drug does not enter the bloodstream.

Clinical characteristics.

Indications. The drug is indicated for neuralgias, myalgias, and arthralgias.

Contraindications. The drug is contraindicated in case of hypersensitivity to procaine and other components of the drug.

Special safety precautions.

Do not apply to damaged skin or skin with signs of allergy. Do not apply to facial skin.

Do not violate the rules for using the medicinal product, as this may harm health.

Interaction with other medicinal products and other types of interactions. Components of the drug (procaine, anestezin) weaken the antibacterial effect of sulfonamide drugs. Enhance the effects of drugs with local anesthetic action.

When using any other medicinal products simultaneously, inform your doctor.

Special precautions for use.

Use during pregnancy or breastfeeding.

During pregnancy and breastfeeding, the use of this medicinal product is possible only if the expected benefit to the mother outweighs the potential risk to the fetus or infant.

Ability to affect reaction speed when driving or operating machinery.
Does not affect.

Method of Administration and Dosage

The medication is intended for topical use. Affected skin areas should be rubbed with Menovazin 2–3 times a day. The duration of treatment depends on the form and severity of the disease, the drug's effectiveness, and the type of therapy (monotherapy or combined with other medicinal agents).

Children. Do not use in children under 12 years of age.

Overdose. Prolonged use may result in dizziness, general weakness, decreased arterial pressure, and allergic reactions. If such symptoms occur, discontinue the medication, wash the residual product from the skin surface with water, and administer symptomatic therapy.

Side effects.

Allergic reactions are possible (hyperemia, skin irritation, sensation of itching, rash, swelling, urticaria).

In case of any adverse events, it is necessary to consult a physician!

Shelf life. 2 years.

The medication must not be used after the expiry date stated on the packaging.

Storage conditions. Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging. 40 ml or 100 ml in glass bottles, 40 ml in polymer bottles.

Availability category. Over-the-counter (without prescription).

Manufacturer: JSC "FITOPHARM".

Manufacturer's address and place of business.
2 Sibirzeva Street, Bakhmut, Donetsk region, 84500, Ukraine.

Marketing Authorization Holder: JSC "FITOPHARM".

Address of the Marketing Authorization Holder.
12 Almatinska Street, Kyiv, 02092, Ukraine.